BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.nebraska.edu

Clinical Trials

Heading Off Peripheral Neuropathy With Exercise

Not Applicable

Terminated

Conditions: Breast Neoplasms
Chemotherapy
Peripheral Nervous System Disorders

Interventions: Behavioral: Aerobic/ Resistance Exercise Intervention
Behavioral: Attention control

First Posted Date: 2009-03-26

Last Posted Date: 2023-12-05

Lead Sponsor: University of Nebraska

Target Recruit Count: 19

Registration Number: NCT00869804

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Clearance of NNAL and Cotinine From Second-hand Smoke in Hair and Urine

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2009-03-18

Last Posted Date: 2023-08-14

Lead Sponsor: University of Nebraska

Registration Number: NCT00863824

Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

Terminated

Conditions: Staphylococcus Aureus

First Posted Date: 2009-03-17

Last Posted Date: 2023-08-23

Lead Sponsor: University of Nebraska

Target Recruit Count: 250

Registration Number: NCT00862862

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging

Completed

Conditions: Heart Disease
Kawasaki Disease

First Posted Date: 2009-03-16

Last Posted Date: 2023-09-25

Lead Sponsor: University of Nebraska

Target Recruit Count: 124

Registration Number: NCT00861848

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer

Phase 1

Completed

Conditions: Recurrent Small Cell Lung Carcinoma

Interventions: Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Topotecan Hydrochloride

First Posted Date: 2009-03-05

Last Posted Date: 2023-09-26

Lead Sponsor: University of Nebraska

Target Recruit Count: 22

Registration Number: NCT00856037

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Regadenoson R-T Perfusion Imaging Trial

Phase 1

Completed

Conditions: Coronary Artery Disease
Myocardial Perfusion Abnormalities

Interventions: Drug: Regadenoson

First Posted Date: 2009-02-05

Last Posted Date: 2024-12-27

Lead Sponsor: University of Nebraska

Target Recruit Count: 100

Registration Number: NCT00837369

Locations: 🇺🇸
University of Nebraska Medicial Center, Omaha, Nebraska, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Arteriovenous Fistula Tissue Bank for Pre- and Post-Fistula Placement Specimens

Completed

Conditions: Kidney Failure, Chronic

Interventions: Other: Biologic specimens

First Posted Date: 2009-02-04

Last Posted Date: 2023-12-28

Lead Sponsor: University of Nebraska

Target Recruit Count: 43

Registration Number: NCT00836862

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Vascular Changes Following Forearm Loop Arteriovenous Graft Placement

Completed

Conditions: Chronic Kidney Disease

First Posted Date: 2009-02-04

Last Posted Date: 2023-09-14

Lead Sponsor: University of Nebraska

Target Recruit Count: 10

Registration Number: NCT00836563

Locations: 🇺🇸
University of Nebraska Medical Center/The Nebraska Medical Center, Omaha, Nebraska, United States

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

Phase 2

Completed

Conditions: Parenteral Nutrition Associated Liver Disease PNALD
Cholestasis

Interventions: Drug: Omegaven™

First Posted Date: 2009-01-21

Last Posted Date: 2023-10-05

Lead Sponsor: University of Nebraska

Target Recruit Count: 72

Registration Number: NCT00826020

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Phase 1

Withdrawn

Conditions: Nonmalignant Neoplasm
Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Lymphoma

Interventions: Drug: cyclosporine
Drug: mycophenolate mofetil
Drug: pentostatin
Genetic: cytogenetic analysis
Genetic: fluorescence in situ hybridization
Genetic: protein analysis
Other: flow cytometry
Other: immunoenzyme technique
Other: laboratory biomarker analysis
Other: reduced-intensity transplant conditioning procedure
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation (PBSC)
Radiation: total-body irradiation

First Posted Date: 2009-01-01

Last Posted Date: 2023-08-14

Lead Sponsor: University of Nebraska

Registration Number: NCT00816413

Home Terms & Conditions Privacy Policy